Stunarone

/ Janssen

Disorders of balance: In adults: 1 tablet of 25 mg t.i.d.
Motion sickness: in adults: 1 tablet of 25 mg half an hour before traveling; to be repeated every 6 hours.
Children (5-12): half of the adult dose is recommended.
STUNARONE should preferably be taken after meals.

Symptomatic treatment of nausea and vertigo due to Meniere’s disease and
other labyrinthine disturbances and for travel sickness.

Hypersensitivity to the active substance or to any of the excipients

As with other antihistamines cinnarizine may cause epigastric distress; taking it after meals may diminish gastric irritation.In patients with Parkinson’s disease cinnarizine should only be given if the advantages outweigh the possible risk of aggravating this disease. Cinnarizine may cause somnolence, especially at the start of treatment. Therefore caution should be taken when alcohol or CNS depressants are used concomitantly. Use of cinnarizine should be avoided in porphyria. There have been no specific studies in hepatic or renal dysfunction. Stugeron should be used with care in patients with hepatic or renal insufficiency. Patients with rare hereditary problems of fructose or galactose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency, should not take this medicine because it contains lactose and sucrose.

Common: Sleepiness, Nausea, Weight increased

Alcohol , CNS depressants and Tricyclic Antidepressants: Concurrent use of alcohol, CNS depressants or tricyclic antidepressants may potentiate the sedative effects of either of these medications or of this medical product.
Diagnostic Interference: Because of its antihistamine effect, cinnarizine may prevent otherwise positive reactions to dermal reactivity indicators if used up to 4 days prior to skin testing.

Pregnancy: As with all drugs, cinnarizine should be used during pregnancy only if the therapeutic benefits outweigh the potential risks for the fetus.
Lactation: There are no data on the excretion of cinnarizine in human breast milk. nursing should therefore be discouraged in women using cinnarizine.
For full details see prescribing information.

Symptoms: The signs and symptoms are mainly due to the anticholinergic (atropine-like) activity of cinnarizine.
Acute cinnarizine overdoses have been reported with doses ranging from 90 to 2,250 mg. The most commonly reported signs and symptoms associated with overdose of cinnarizine include: alterations in consciousness ranging from
somnolence to stupor and coma, vomiting, extrapyramidal symptoms, and hypotonia. In a small number of young children, seizures developed. Clinical consequences were not severe in most cases, but deaths have been reported after single and polydrug overdoses involving cinnarizine.
Treatment: There is no specific antidote. For any overdose, the treatment is symptomatic and supportive care.
Activated charcoal should only be considered in patients presenting within one hour of taking a potentially toxic overdose (ie more than 15mg/kg).